Cited by 274Neuroendocrine Tumor Research AdvancesRadiopharmaceutical Chemistry and ApplicationsMedical Imaging Techniques and Applications

The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.

Somatostatin receptor antagonists for imaging and therapy.

Open access

Fani, Melpomeni, Nicolas, Guillaume P., Wild, Damian·2017·Journal of Nuclear Medicine

DOI 10.2967/jnumed.116.186783

Open this paper in CoChat — free account Open PDF

Abstract

Somatostatin receptor (sstr) scintigraphy for imaging and sstr analogs for treatment have been used for more than 20 y. An important improvement in recent years was the introduction of peptide receptor radionuclide therapy with radiolabeled sstr agonists, such as [90Y-DOTA0,Tyr3]octreotide or [177Lu-DOTA0,Tyr3]octreotide (90Y- or 177Lu-DOTATOC, respectively) and [177Lu-DOTA0,Tyr3]octreotate (177Lu-DOTATATE). PET/CT with 68Ga-labeled sstr agonists, such as 68Ga-DOTATOC, 68Ga-DOTATATE, and [68Ga-DOTA,1-Nal3]octreotide (68Ga-DOTANOC), plays an important role in staging and restaging neuroendocrine tumors. Most importantly, sstr scintigraphy and sstr PET/CT can distinguish patients who will qualify for and benefit from peptide receptor radionuclide therapy. This characteristic of sstr targeting is important because it allows a personalized treatment approach (theranostic approach). Until recently, it was thought that internalization of the radiolabeled agonist was mandatory for sstr-mediated imaging and therapy. It was Ginj et al. who proposed in 2006 the paradigm shift that radiolabeled sstr antagonists may perform better than agonists despite the lack of internalization. Despite the rather limited number of head-to-head comparisons of sstr antagonists and agonists, the superiority of sstr antagonists was demonstrated in several cases. From a small library of sstr antagonists, the analog JR11 (Cpa-c[d-Cys-Aph(Hor)-d-Aph(Cbm)-Lys-Thr-Cys]-d-Tyr-NH2), an antagonist with selectivity for sstr subtype 2, showed the best overall characteristics for sstr subtype 2 targeting and was therefore selected for clinical translation. JR11 is under clinical development as a PET imaging agent when labeled with 68Ga (68Ga-NODAGA-JR11 or 68Ga-OPS202) and as a therapeutic agent when labeled with 177Lu (177Lu-DOTA-JR11 or 177Lu-OPS201). In this article, we discuss the development and current status of radiolabeled sstr antagonists. Evidence based on preclinical work, on quantitative in vivo autoradiography of human tumor slices, and on human data now supports a shift to sstr antagonists.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.2967/jnumed.116.186783

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308
Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use
Reubi, J. C., Schär, J.-C., Waser, B., Wenger, S., Heppeler, A., Schmitt, J. S., & Mäcke, H. R. (2000) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050034 · Cited by 1,127
ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site
Pavel, M. E., O’Toole, D., Costa, F. P., Capdevila, J., Gross, D., Kianmanesh, R., Krenning, E. P., Knigge, U., Salazar, R., Pape, U., et al. (2016) · Neuroendocrinology · doi:10.1159/000443167 · Cited by 1,038
Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors
Ginj, M., Zhang, H., Waser, B., Cescato, R., Wild, D., Wang, X., Érchegyi, J., Rivier, J., Mäcke, H. R., & Reubi, J. C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607761103 · Cited by 526
Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?
Antunes, P., Ginj, M., Zhang, H., Waser, B., Baum, R. P., Reubi, J. C., & Maëcke, H. R. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0317-x · Cited by 395
Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study
Wild, D., Fani, M., Fischer, R., Pozzo, L. D., Kaul, F., Krebs, S. S., Fischer, R., Rivier, J., Reubi, J. C., Maëcke, H. R., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.138834 · Cited by 267
PET of Somatostatin Receptor–Positive Tumors Using 64Cu- and 68Ga-Somatostatin Antagonists: The Chelate Makes the Difference
Fani, M., Pozzo, L. D., Abiraj, K., Mansi, R., Tamma, M. L., Cescato, R., Waser, B., Weber, W., Reubi, J. C., & Maëcke, H. R. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.087999 · Cited by 264
Radiopeptide Imaging and Therapy in Europe
Ambrosini, V., Fani, M., Fanti, S., Forrer, F., & Maëcke, H. R. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.085753 · Cited by 201
First Clinical Evidence That Imaging with Somatostatin Receptor Antagonists Is Feasible
Wild, D., Fani, M., Béhé, M. P., Brink, I., Rivier, J., Reubi, J. C., Maëcke, H. R., & Weber, W. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.088922 · Cited by 184
Unexpected Sensitivity of sst2 Antagonists to N-Terminal Radiometal Modifications
Fani, M., Braun, F., Waser, B., Beetschen, K., Cescato, R., Erchegyi, J., Rivier, J. E., Weber, W. A., Maecke, H. R., & Reubi, J. C. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.102764 · Cited by 172
Self-citation

Show all 24 references

Research works printed but not linked: 1

Nicolas, 2015, Wider safety window with radiolabeled somatostatin receptor antagonists over agonists [abstract], J Nucl Med., 56, 335

Sorted by citations

Radiopharmaceutical therapy in cancer: clinical advances and challenges
Sgouros, G., Bodei, L., McDevitt, M. R., & Nedrow, J. R. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0073-9 · Cited by 1,032
European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma
Taïeb, D., Hicks, R. J., Hindié, E., Guillet, B. A., Avram, A. M., Ghedini, P., Timmers, H. J. L. M., Scott, A. T., Elojeimy, S. N., Rubello, D., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04398-1 · Cited by 420
Consensus on molecular imaging and theranostics in neuroendocrine neoplasms
Ambrosini, V., Kunikowska, J., Baudin, É., Bodei, L., Bouvier, C., Capdevila, J., Cremonesi, M., de Herder, W. W., Dromain, C., Falconi, M., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.008 · Cited by 254
A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements
Burkett, B. J., Bartlett, D. J., McGarrah, P. W., Lewis, A. R., Johnson, D. R., Berberoğlu, K., Pandey, M. K., Packard, A. T., Halfdanarson, T. R., Hruska, C. B., et al. (2023) · Radiology Imaging Cancer · doi:10.1148/rycan.220157 · Cited by 238
Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future
Stueven, A. K., Kayser, A., Wetz, C., Amthauer, H., Wree, A., Tacke, F., Wiedenmann, B. J., Roderburg, C., & Jann, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20123049 · Cited by 219
Targeted α -Emitter Therapy with 212 Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial
Delpassand, E. S., Tworowska, I., Esfandiari, R., Torgue, J., Hurt, J., Shafie, A., & Núñez, R. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263230 · Cited by 199
Sensitivity Comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study
Nicolas, G. P., Schreiter, N. F., Kaul, F., Uiters, J., Bouterfa, H., Kaufmann, J., Erlanger, T. E., Cathomas, R. L., Christ, E., Fani, M., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.199760 · Cited by 174
Somatostatin receptor PET ligands - the next generation for clinical practice.
Pauwels, E., Cleeren, F., Bormans, G. M., & Deroose, C. M. (2018) · Europe PMC (PubMed Central) · Cited by 138
First-in-Humans Study of the SSTR Antagonist 177Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy
Baum, R. P., Zhang, J., Schuchardt, C., Müller, D., & Mäcke, H. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.258889 · Cited by 127
Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy
Eychenne, R., Bouvry, C., Bourgeois, M., Loyer, P., Benoist, É., & Lepareur, N. (2020) · Molecules · doi:10.3390/molecules25174012 · Cited by 133
Challenges and Opportunities in the Delivery of Cancer Therapeutics: Update on Recent Progress
Lorscheider, M., Gaudin, A., Nakhlé, J., Veiman, K.-L., Richard, J., & Chassaing, C. (2020) · Therapeutic Delivery · doi:10.4155/tde-2020-0079 · Cited by 113
Nanoparticles for Cancer Diagnosis, Radionuclide Therapy and Theranostics
Llop, J., & Lammers, T. (2021) · ACS Nano · doi:10.1021/acsnano.1c09139 · Cited by 107
Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies
Lee, L., Ito, T., & Jensen, R. T. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1496822 · Cited by 102
Theranostic Nuclear Medicine with Gallium-68, Lutetium-177, Copper-64/67, Actinium-225, and Lead-212/203 Radionuclides
Morgan, K. A., Rudd, S. E., Noor, A., & Donnelly, P. S. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00456 · Cited by 101
Head-to-Head Comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: A Prospective Study
Zhu, W., Cheng, Y., Wang, X., Yao, S., Bai, C., Zhao, H., Jia, R., Xu, J., & Huo, L. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.235093 · Cited by 87
Clinical Advances and Perspectives in Targeted Radionuclide Therapy
Lepareur, N., Ramée, B., Mougin‐Degraef, M., & Bourgeois, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061733 · Cited by 86
Recent advances in theranostics and challenges for the future
Turner, J. H. (2018) · British Journal of Radiology · doi:10.1259/bjr.20170893 · Cited by 79
Radiolabeled Peptides and Antibodies in Medicine
Kręcisz, P., Czarnecka, K., Królicki, L., Mikiciuk‐Olasik, E., & Szymański, P. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00617 · Cited by 76
State-of-the-Art Imaging in Human Chordoma of the Skull Base
Santegoeds, R. G. C., Temel, Y., Beckervordersandforth, J. C., van Overbeeke, J. J., & Hoeberigs, M. C. (2018) · Current Radiology Reports · doi:10.1007/s40134-018-0275-7 · Cited by 75
Peptide Receptor Radionuclide Therapy with 67Cu-CuSarTATE Is Highly Efficacious Against a Somatostatin-Positive Neuroendocrine Tumor Model
Cullinane, C. M., Jeffery, C. M., Roselt, P. D., van Dam, E. M., Jackson, S., Kuan, K., Jackson, P. A., Binns, D., Zuylekom, J. V., Harris, M. J., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.243543 · Cited by 76
Versatile Functions of Somatostatin and Somatostatin Receptors in the Gastrointestinal System
Shamsi, B. H., Chatoo, M., Xu, X. K., Xu, X., & Chen, X. Q. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.652363 · Cited by 71
Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies
Auernhammer, C. J., Spitzweg, C., Angele, M. K., Boeck, S. H., Grossman, A. B., Nölting, S., Ilhan, H., Knösel, T., Mayerle, J. V., Reincke, M., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30401-1 · Cited by 70
Peptide receptor radionuclide therapy for patients with advanced pancreatic neuroendocrine tumors
Ramage, J. K., Naraev, B. G., & Halfdanarson, T. R. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.08.004 · Cited by 70
Revisiting Weight-Normalized SUV and Lean-Body-Mass–Normalized SUV in PET Studies
Sarikaya, İ., Albatineh, A. N., & Sarıkaya, A. (2019) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.119.233353 · Cited by 72
An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors
Alshaikh, O. M., Asa, S. L., Mete, Ö., & Ezzat, S. (2019) · Endocrine Pathology · doi:10.1007/s12022-019-9568-5 · Cited by 70
Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists
Shi, M., Jakobsson, V., Greifenstein, L., Khong, P.-L., Chen, X., Baum, R. P., & Zhang, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1034315 · Cited by 68
New Developments in Peptide Receptor Radionuclide Therapy
Nicolas, G. P., Morgenstern, A., Schottelius, M., & Fani, M. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.213496 · Cited by 67
Pheochromocytoma/paraganglioma: recent updates in genetics, biochemistry, immunohistochemistry, metabolomics, imaging and therapeutic options
Antonio, K. L., Valdez, M. M. N., MERCADO-ASIS, L. B., Taïeb, D., & Pacák, K. (2020) · Gland Surgery · doi:10.21037/gs.2019.10.25 · Cited by 65
Peptide Receptor Radionuclide Therapy as a Novel Treatment for Metastatic and Invasive Phaeochromocytoma and Paraganglioma
Mak, I. Y. F., Hayes, A. R., Khoo, B. C. E., & Grossman, A. B. (2019) · Neuroendocrinology · doi:10.1159/000499497 · Cited by 59
Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy
Hu, Y., Ye, Z., Wang, F., Qin, Y., Xu, X.-W., Yu, X.-J., & Ji, S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.679000 · Cited by 56
Neurokinin-1 receptor promotes non-small cell lung cancer progression through transactivation of EGFR
Zhang, X.-W., Li, L., Hu, W.-Q., Hu, M.-N., Tao, Y., Hu, H., Miao, X.-K., Yang, W.-L., Zhu, Q., & Mou, L. (2022) · Cell Death and Disease · doi:10.1038/s41419-021-04485-y · Cited by 59
18F-AlF Labeled Peptide and Protein Conjugates as Positron Emission Tomography Imaging Pharmaceuticals
Kumar, K., & Ghosh, A. K. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00817 · Cited by 56
Emerging and Novel Treatments for Pituitary Tumors
Ilie, M. D., Lasolle, H., & Raverot, G. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8081107 · Cited by 56
Imaging-guided targeted radionuclide tumor therapy: From concept to clinical translation
Sun, J., Huangfu, Z., Yang, J., Wang, G., Hu, K., Gao, M., & Zhong, Z. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114538 · Cited by 57
Neuropeptide G Protein-Coupled Receptors as Oncotargets
Moody, T. W., Ramos-Álvarez, I., & Jensen, R. T. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00345 · Cited by 54
From Bench to Bedside—The Bad Berka Experience With First-in-Human Studies
Zhang, J., Singh, A., Kulkarni, H., Schuchardt, C., Müller, D., Wester, H.-J., Μάινα, Θ., Rösch, F., van der Meulen, N. P., Müller, C., et al. (2019) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2019.06.002 · Cited by 54
Theranostic Concepts: More Than Just a Fashion Trend—Introduction and Overview
Herrmann, K., Larson, S. M., & Weber, W. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.199570 · Cited by 51
Targeted Radionuclide Therapy: New Advances for Improvement of Patient Management and Response
Malcolm, J., Falzone, N., Lee, B. Q., & Vallis, K. A. (2019) · Cancers · doi:10.3390/cancers11020268 · Cited by 52
Peptide Receptor Radionuclide Therapy for Patients With Advanced Lung Carcinoids
Naraev, B. G., Ramirez, R. A., Kendi, A. T., & Halfdanarson, T. R. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.02.007 · Cited by 51
Structural insights into ligand recognition and selectivity of somatostatin receptors
Zhao, W., Han, S., Qiu, N., Feng, W., Lu, M., Zhang, W., Wang, M., Zhou, Q., Chen, S., Xü, W., et al. (2022) · Cell Research · doi:10.1038/s41422-022-00679-x · Cited by 50
Peptide Receptor Radionuclide Therapy
Hofland, J., Brabander, T., Verburg, F. A., Feelders, R. A., & de Herder, W. W. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac574 · Cited by 50
GPCR Modulation in Breast Cancer
Lappano, R., Jacquot, Y., & Maggiolini, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123840 · Cited by 51
Combination of 5-Fluorouracil with Epigenetic Modifiers Induces Radiosensitization, Somatostatin Receptor 2 Expression, and Radioligand Binding in Neuroendocrine Tumor Cells In Vitro
Jin, X., Auernhammer, C. J., Ilhan, H., Lindner, S., Nölting, S., Maurer, J., Spöttl, G., & Orth, M. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.224048 · Cited by 50
Therapy With 177Lu-DOTATATE: Clinical Implementation and Impact on Care of Patients With Neuroendocrine Tumors
Kendi, A. T., Halfdanarson, T. R., Packard, A. T., Dundar, A., & Subramaniam, R. M. (2019) · American Journal of Roentgenology · doi:10.2214/ajr.19.21123 · Cited by 50
Strategies for improving stability and pharmacokinetic characteristics of radiolabeled peptides for imaging and therapy
Gharibkandi, N. A., Conlon, J. M., & Hosseinimehr, S. J. (2020) · Peptides · doi:10.1016/j.peptides.2020.170385 · Cited by 49
Radiotheranostics Coupled between an At-211-Labeled RGD Peptide and the Corresponding Radioiodine-Labeled RGD Peptide
Ogawa, K., Takeda, T., Mishiro, K., Toyoshima, A., Shiba, K., Yoshimura, T., Shinohara, A., Kinuya, S., & Odani, A. (2019) · ACS Omega · doi:10.1021/acsomega.8b03679 · Cited by 48
The Search for an Alternative to [68Ga]Ga-DOTA-TATE in Neuroendocrine Tumor Theranostics: Current State of 18F-labeled Somatostatin Analog Development
Waldmann, C. M., Stuparu, A. D., van Dam, R. M., & Slavik, R. (2019) · Theranostics · doi:10.7150/thno.31806 · Cited by 47
Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists
Nock, B. A., Kanellopoulos, P., Joosten, L., Mansi, R., & Μάινα, Θ. (2023) · Pharmaceuticals · doi:10.3390/ph16050674 · Cited by 46
Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements
Merola, E., & Grana, C. M. (2023) · Cancers · doi:10.3390/cancers15112975 · Cited by 44
Treatment With 90Y/177Lu-DOTATOC in Patients With Metastatic Adrenocortical Carcinoma Expressing Somatostatin Receptors
Grisanti, S., Filice, A., Basile, V., Cosentini, D., Rapa, I., Albano, D., Morandi, A., Laganà, M., Volta, A. D., Bertagna, F., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz091 · Cited by 42
Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors
Ambrosini, V., Zanoni, L., Filice, A., Lamberti, G., Argalia, G., Fortunati, E., Campana, D., Versari, A., & Fanti, S. (2022) · Cancers · doi:10.3390/cancers14041055 · Cited by 42
Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours
Adant, S., Shah, G. M., & Beauregard, J. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04499-x · Cited by 41
Management of NFAs: medical treatment
Even-Zohar, N., & Greenman, Y. (2018) · Pituitary · doi:10.1007/s11102-018-0865-7 · Cited by 40
A prospective randomized, double-blind study to evaluate the diagnostic efficacy of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with 68Ga-DOTATATE
Zhu, W., Jia, R., Yang, Q., Cheng, Y., Zhao, H., Bai, C., Xu, J., Yao, S., & Huo, L. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05512-y · Cited by 40
Theranostics in neuroendocrine tumours: somatostatin receptor imaging and therapy
Pencharz, D., Gnanasegaran, G., & Navalkissoor, S. (2018) · British Journal of Radiology · doi:10.1259/bjr.20180108 · Cited by 38
177Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer
Thakur, S., Daley, B., Millo, C., Cochran, C. S., Jacobson, O., Lü, H., Wang, Z., Kiesewetter, D. O., Chen, X. S., Vasko, V. V., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3453 · Cited by 38
A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors
Zhu, W., Cheng, Y., Jia, R., Zhao, H., Bai, C., Xu, J., Yao, S., & Huo, L. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.253096 · Cited by 38
Cholecystokinin-2 Receptor Targeting with Radiolabeled Peptides: Current Status and Future Directions
Klingler, M., Hörmann, A. A., & von Guggenberg, E. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200625143035 · Cited by 36
Somatostatin Receptor Targeted PET-CT and Its Role in the Management and Theranostics of Gastroenteropancreatic Neuroendocrine Neoplasms
Adnan, A., & Basu, S. K. (2023) · Diagnostics · doi:10.3390/diagnostics13132154 · Cited by 35
Tumor targeting with 99m Tc radiolabeled peptides: Clinical application and recent development
Rezazadeh, F., & Sadeghzadeh, N. (2018) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13413 · Cited by 35
Development of Diagnostic and Therapeutic Probes with Controlled Pharmacokinetics for Use in Radiotheranostics
Ogawa, K. (2019) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c19-00274 · Cited by 35
Prognostic Value of Maximum Standardized Uptake Value in 68Ga-Somatostatin Receptor Positron Emission Tomography for Neuroendocrine Tumors
Lee, D. Y., & Kim, Y.-I. (2019) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002694 · Cited by 34
Treatment Options for Gonadotroph Tumors: Current State and Perspectives
Ilie, M. D., & Raverot, G. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa497 · Cited by 32
Novel PET tracers: added value for endocrine disorders
Bergeret, S., Charbit, J., Ansquer, C., Bera, G. C., Chanson, P., & Lussey‐Lepoutre, C. (2019) · Endocrine · doi:10.1007/s12020-019-01895-z · Cited by 31
Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals
von Guggenberg, E., Peitl, P. K., Rottenburger, C., Mikołajczak, R., & Hubalewska–Dydejczyk, A. (2021) · Cancers · doi:10.3390/cancers13225776 · Cited by 31
Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors
Das, S., & Dasari, A. N. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211018047 · Cited by 30
Primary Retroperitoneal Ganglioneuroma: A Retrospective Cohort Study of 32 Patients
Xiao, J., Zhao, Z., Li, B., & Zhang, T. (2021) · Frontiers in Surgery · doi:10.3389/fsurg.2021.642451 · Cited by 30
Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [177Lu]Lu-OPS201 Compared to the Agonist [177Lu]Lu-DOTA-TATE
Mansi, R., Plas, P., Vauquelin, G., & Fani, M. (2021) · Pharmaceuticals · doi:10.3390/ph14121265 · Cited by 30
Design and development of the theranostic pair 177Lu‐OPS201/68Ga‐OPS202 for targeting somatostatin receptor expressing tumors
Mansi, R., & Fani, M. (2019) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3755 · Cited by 30
“Albumin Hitchhiking” with an Evans Blue Analog for Cancer Theranostics
Ehlerding, E. B., Lan, X., & Cai, W. (2017) · Theranostics · doi:10.7150/thno.24183 · Cited by 29
Construction of Targeting-Peptide-Based Imaging Reagents and Their Application in Bioimaging
Zhang, L., Wang, X., Zhao, J., Sun, B., & Wang, W. (2023) · Chemical & Biomedical Imaging · doi:10.1021/cbmi.3c00104 · Cited by 28
Targeted Radionuclide Therapy in Glioblastoma
Zhao, X., Jakobsson, V., Tao, Y., Zhao, T., Wang, J., Khong, P., Chen, X. S., & Zhang, J. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c07850 · Cited by 27
Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects
Mazziotti, G., Mosca, A., Frara, S., Vitale, G., & Giustina, A. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1391217 · Cited by 27
Immunohistochemical Profile and 47-Gene Next-Generation Sequencing (NGS) Solid Tumor Panel Analysis of a Series of 13 Strumal Carcinoids
Theurer, S., Ingenwerth, M., Herold, T., Herrmann, K., & Schmid, K. W. (2020) · Endocrine Pathology · doi:10.1007/s12022-020-09608-3 · Cited by 27
Bio-vehicles of cytotoxic drugs for delivery to tumor specific targets for cancer precision therapy
Al-Mansoori, L., Elsinga, P. H., & Goda, S. K. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112260 · Cited by 28
68 Ga/ 177 Lu-Labeled Theranostic Pair for Targeting Fibroblast Activation Protein with Improved Tumor Uptake and Retention
Huang, J., Zhang, X., Liu, Q., Gong, F., Huang, Y., Huang, S., Fu, L., & Tang, G. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01812 · Cited by 26
Dual-Targeted Extracellular Vesicles to Facilitate Combined Therapies for Neuroendocrine Cancer Treatment
Si, Y., Guan, J.-S., Xu, Y., Chen, K., Kim, S., Zhou, L., Jaskula‐Sztul, R., & Liu, M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12111079 · Cited by 26
Peptide Receptor Radionuclide Therapy and Primary Brain Tumors: An Overview
Cimini, A., Ricci, M., Russo, F., Egidi, M., Calabria, F. F., Bagnato, A., Schillaci, O., & Chiaravalloti, A. (2021) · Pharmaceuticals · doi:10.3390/ph14090872 · Cited by 26
Octreotide Conjugates for Tumor Targeting and Imaging
Figueras, E., Martins, A., Borbély, A., Joncour, V. L., Cordella, P., Perego, R., Modena, D., Pagani, P., Esposito, S., Auciello, G., et al. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11050220 · Cited by 26
Comparison of the tolerability of 161Tb- and 177Lu-labeled somatostatin analogues in the preclinical setting
Busslinger, S. D., Mapanao, A. K., Kegler, K., Bernhardt, P., Flühmann, F., Fricke, J., Zeevaart, J. R., Köster, U., van der Meulen, N. P., Schibli, R., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06827-2 · Cited by 25
Comparative evaluation of 68Ga-labelled TATEs: the impact of chelators on imaging
Xia, Y., Zeng, C., Zhao, Y., Zhang, X., Li, Z., & Chen, Y. (2020) · EJNMMI Research · doi:10.1186/s13550-020-00620-6 · Cited by 24
Gallium-68 labeled somatostatin receptor antagonist PET/CT in over 500 patients with neuroendocrine neoplasms: experience from a single center in China
Liu, M., Cheng, Y., Bai, C., Zhao, H., Jia, R., Chen, J., Zhu, W., & Huo, L. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06639-4 · Cited by 24
Somatostatin receptor targeting with hydrophilic [99mTc/186Re]Tc/Re-tricarbonyl NODAGA and NOTA complexes
Makris, G., Kuchuk, M., Gallazzi, F., Jurisson, S. S., Smith, C. J., & Hennkens, H. M. (2019) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2019.04.004 · Cited by 24
68Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study
Kersting, D., Sandach, P., Sraieb, M., Wiesweg, M., Metzenmacher, M., Darwiche, K., Oezkan, F., Bölükbas, S., Stuschke, M., Umutlu, L., et al. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265664 · Cited by 17
Detection and therapy of neuroblastoma minimal residual disease using [64/67Cu]Cu-SARTATE in a preclinical model of hepatic metastases
Dearling, J. L. J., van Dam, E. M., Harris, M. J., & Packard, A. B. (2021) · EJNMMI Research · doi:10.1186/s13550-021-00763-0 · Cited by 22
Development of a Novel HER2-Targeted Peptide Probe for Dual-Modal Imaging of Tumors
Cao, R., Li, R., Lai, C., Shi, H., Liu, H., & Cheng, Z. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00347 · Cited by 23
First preclinical evaluation of [225Ac]Ac-DOTA-JR11 and comparison with [177Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs
Handula, M., Beekman, S., Konijnenberg, M., Stuurman, D. C., de Ridder, C., Bruchertseifer, F., Morgenstern, A., Denkova, A. G., de Blois, E., & Seimbille, Y. (2023) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-023-00197-0 · Cited by 21
Review: PET imaging with macro- and middle-sized molecular probes
Mukai, H., & Watanabe, Y. (2020) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2020.06.007 · Cited by 21
PET/CT and PET/MRI in neuroendocrine neoplasms
Rajamohan, N., Khasawneh, H., Singh, A., Suman, G., Johnson, G. B., Majumder, S., Halfdanarson, T. R., & Goenka, A. H. (2022) · Abdominal Radiology · doi:10.1007/s00261-022-03516-2 · Cited by 20
Clinical characteristics and outcome of primary hepatic neuroendocrine tumors after comprehensive therapy
Wang, H., Liu, Z.-C., Zhang, G., Li, L.-H., Li, L., Meng, Q., Wang, P.-J., Shen, D., & Dang, X. (2020) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v12.i9.1031 · Cited by 20
A physiologically based pharmacokinetic (PBPK) model to describe organ distribution of 68Ga-DOTATATE in patients without neuroendocrine tumors
Siebinga, H., der Veen, B. J. D. W., Beijnen, J. H., Stokkel, M. P. M., Dorlo, T. P. C., Huitema, A. D. R., & Hendrikx, J. J. M. A. (2021) · EJNMMI Research · doi:10.1186/s13550-021-00821-7 · Cited by 20
Emerging innovations in theranostics for pancreatic neuroendocrine tumors
Karimi, A., Bogdani, C., O’Dwyer, E., & Siolas, D. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00938-1 · Cited by 23
The Emergence of Somatostatin Antagonist–Based Theranostics: Paving the Road Toward Another Success?
Impériale, A., Jha, A., Meuter, L., Nicolas, G. P., Taïeb, D., & Pacák, K. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265406 · Cited by 19
Current Status and Perspectives of Novel Radiopharmaceuticals with Heterologous Dual-targeted Functions: 2013–2023
Li, Z., Ruan, Q. Z., Jiang, Y., Wang, Q., Yin, G., Feng, J., & Zhang, J. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01608 · Cited by 19
Nonneuroendocrine Neoplasms of the Pituitary Region
Kaltsas, G., Kolomodi, D., Randeva, H. S., & Grossman, A. B. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01871 · Cited by 19
Trends in cancer imaging
Zhou, X., Shi, B., Huang, G., Liu, J., & Wei, W. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.08.006 · Cited by 18
Synthesis and characterization of natural lanthanum labelled DOTA-Peptides for simulating radioactive Ac-225 labeling
Uçar, B. (2019) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2019.108816 · Cited by 18
Designing poly-agonists for treatment of metabolic diseases: challenges and opportunities
Petersen, J., Strømgaard, K., Frølund, B., & Clemmensen, C. (2019) · Drugs · doi:10.1007/s40265-019-01153-6 · Cited by 17
Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms
Olmo-García, M. I. D., Prado-Wohlwend, S., Andrés, A. T., Soriano, J. M., Belló, P., & Merino-Torres, J. F. (2021) · Biomedicines · doi:10.3390/biomedicines9121810 · Cited by 17
Head-to-Head Comparison of 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT in Patients With Tumor-Induced Osteomalacia: A Prospective Study
Hou, G., Zhang, Y., Liu, Y., Wang, P., Xia, W., Xing, X., Huo, L., Li, F., & Jing, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.811209 · Cited by 17

Authors: Fani, M., Nicolas, G. P., & Wild, D.
Affiliations: University Hospital of Basel (CH)
ORCID: Fani, Melpomeni
Wild, Damian
Venue: Journal of Nuclear Medicine
Publisher: Society of Nuclear Medicine
Published: 2017-09
Volume: 58
Issue: Supplement 2
Pages: 61S-66S
ISSN: 0161-5505 (ISSN-L)
2159-662X
DOI: 10.2967/jnumed.116.186783
OpenAlex: W2752482655
Cited by: 274
References: 24
Citations by year: 2026: 15 · 2025: 31 · 2024: 27 · 2023: 38 · 2022: 21 · 2021: 36 · 2020: 39 · 2019: 37 · 2018: 24 · 2017: 5
FWCI: 22.48
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Nuclear Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords: somatostatin receptor antagonists, somatostatin receptor scintigraphy, peptide receptor radionuclide therapy, neuroendocrine tumors, theranostics, 68Ga-DOTATOC, 177Lu-DOTATOC, receptor internalization, somatostatin receptor 2, radiolabeled somatostatin analogs
MeSH terms: Animals, Diagnostic Imaging, Humans, Isotope Labeling, Receptors, Somatostatin, Drug Discovery, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Somatostatin receptor antagonists for imaging and therapy.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks